Diagnosis and Treatment for Mild Cognitive Impairment: A Systematic Review of Clinical Practice Guidelines and Consensus Statements

被引:77
作者
Chen, Ya-Xin [1 ]
Liang, Ning [1 ]
Li, Xiao-Ling [2 ]
Yang, Si-Hong [1 ]
Wang, Yan-Ping [1 ]
Shi, Nan-Nan [1 ]
机构
[1] China Acad Chinese Med Sci, Inst Basic Res Clin Med, Beijing, Peoples R China
[2] Shaanxi Univ Chinese Med, Sch Clin Med 1, Xianyang, Shaanxi, Peoples R China
来源
FRONTIERS IN NEUROLOGY | 2021年 / 12卷
关键词
diagnosis; guidelines; mild cognitive impairment; therapeutic; systematic review; ALZHEIMERS-DISEASE; AMERICAN-ACADEMY; ASSESSMENT MOCA; AGREE II; RECOMMENDATIONS; SUPPORT; TOOLS; SUBCOMMITTEE; METAANALYSIS; ASSOCIATION;
D O I
10.3389/fneur.2021.719849
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Mild cognitive impairment (MCI) is an important stage between the normal cognitive decline of aging and dementia. The aim of this study was to compare and harmonize the recommendations for the diagnosis and treatment of MCI based on current clinical practice guidelines. Methods: We searched the PubMed, EMBASE, China National Knowledge Infrastructure, Wanfang Database, Chinese Science and Technology Periodical Database, and Chinese Biological Medicine Database from their inception date to April 24, 2021 to identify all published guidelines on MCI. The qualities of the eligible guidelines were appraised by two reviewers using the Appraisal of Guidelines for Research and Evaluation II instrument. Results: Thirteen guidance documents (four guidelines and nine consensus statements) with specific recommendations were included. Nine guidelines and consensus statements covered the screening and diagnosis of MCI. The evaluation of the documents showed that neuropsychological testing and biomarker assessments were the most common recommendations for the diagnosis of MCI. Nine of the 13 guidance documents covered the treatment and management of MCI. The recommendations for the treatment and management were classified into four categories, namely: intervention for risk reduction, pharmacologic interventions, non-pharmacologic interventions, and counseling. Regarding pharmacological interventions, three guidelines recommend no pharmacologic intervention. The use of cholinesterase inhibitors for MCI is contraindicated in three guidance documents, whereas one proposes that cholinesterase inhibitors and memantine should be deprescribed. EHb761, Chinese herbal decoctions, and Chinese traditional patent medicine are recommended in two documents. A total of seven guidance documents recommend non-pharmacological interventions, including physical activity interventions, cognitive interventions, dietary and nutritional interventions, and acupuncture. Conclusion: An updated search for possible evidence on the diagnosis and treatment of MCI is needed. Potentially effective diagnoses and treatments, either conventional or complementary, and alternative therapies should be highly valued and addressed in correlation with the supporting evidence.
引用
收藏
页数:12
相关论文
共 44 条
  • [11] Souvenaid in the management of mild cognitive impairment: an expert consensus opinion
    Cummings, Jeffrey
    Passmore, Peter
    McGuinness, Bernadette
    Mok, Vincent
    Chen, Christopher
    Engelborghs, Sebastiaan
    Woodward, Michael
    Manzano, Sagrario
    Garcia-Ribas, Guillermo
    Cappa, Stefano
    Bertolucci, Paulo
    Chu, Leung-Wing
    [J]. ALZHEIMERS RESEARCH & THERAPY, 2019, 11 (01)
  • [12] Do CSF total tau, phosphorylated tau, and β-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer's disease?: A systematic review and meta-analysis of the literature
    Diniz, Breno S. O.
    Pinto, Jony A., Jr.
    Forlenza, Orestes Vicente
    [J]. WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2008, 9 (03) : 172 - 182
  • [13] Mild Cognitive Impairment: the Manchester consensus
    Dunne, Ross A.
    Aarsland, Dag
    O'Brien, John T.
    Ballard, Clive
    Banerjee, Sube
    Fox, Nick C.
    Isaacs, Jeremy D.
    Underwood, Benjamin R.
    Perry, Richard J.
    Chan, Dennis
    Dening, Tom
    Thomas, Alan J.
    Schryer, Jeffrey
    Jones, Anne-Marie
    Evans, Alison R.
    Alessi, Charles
    Coulthard, Elizabeth J.
    Pickett, James
    Elton, Peter
    Jones, Roy W.
    Mitchell, Susan
    Hooper, Nigel
    Kalafatis, Chris
    Rasmussen, Jill G. C.
    Martin, Helen
    Schott, Jonathan M.
    Burns, Alistair
    [J]. AGE AND AGEING, 2021, 50 (01) : 72 - 80
  • [14] Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance
    Ewers, Michael
    Walsh, Cathal
    Trojanowski, John Q.
    Shaw, Leslie M.
    Petersen, Ronald C.
    Jack, Clifford R., Jr.
    Feldman, Howard H.
    Bokde, Arun L. W.
    Alexander, Gene E.
    Scheltens, Philip
    Vellas, Bruno
    Dubois, Bruno
    Weiner, Michael
    Hampel, Harald
    [J]. NEUROBIOLOGY OF AGING, 2012, 33 (07) : 1203 - +
  • [15] A randomized controlled trial of Kundalini yoga in mild cognitive impairment
    Eyre, Harris A.
    Siddarth, Prabha
    Acevedo, Bianca
    Van Dyk, Kathleen
    Paholpak, Pattharee
    Ercoli, Linda
    St Cyr, Natalie
    Yang, Hongyu
    Khalsa, Dharma S.
    Lavretsky, Helen
    [J]. INTERNATIONAL PSYCHOGERIATRICS, 2017, 29 (04) : 557 - 567
  • [16] Role of Fluid Biomarkers and PET Imaging in Early Diagnosis and its Clinical Implication in the Management of Alzheimer's Disease
    Hameed, Shahul
    Fuh, Jong-Ling
    Senanarong, Vorapun
    Ebenezer, Esther Gunaseli M.
    Looi, Irene
    Dominguez, Jacqueline C.
    Park, Kyung Won
    Karanam, Ananda Krishna
    Simon, Oliver
    [J]. JOURNAL OF ALZHEIMERS DISEASE REPORTS, 2020, 4 (01) : 21 - 37
  • [17] Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment
    Herukka, Sanna-Kaisa
    Simonsen, Anja Hviid
    Andreasen, Niels
    Baldeiras, Ines
    Bjerke, Maria
    Blennow, Kaj
    Engelborghs, Sebastiaan
    Frisoni, Giovanni B.
    Gabryelewicz, Tomasz
    Galluzzi, Samantha
    Handels, Ron
    Kramberger, Milica G.
    Kulczynska, Agnieszka
    Luis Molinuevo, Jose
    Mroczko, Barbara
    Nordberg, Agneta
    Oliveira, Catarina Resende
    Otto, Markus
    Rinne, Juha O.
    Rot, Uros
    Saka, Esen
    Soininen, Hilkka
    Struyfs, Hanne
    Suardi, Silvia
    Visser, Pieter Jelle
    Winblad, Bengt
    Zetterberg, Henrik
    Waldemar, Gunhild
    [J]. ALZHEIMERS & DEMENTIA, 2017, 13 (03) : 285 - 295
  • [18] Recommendation of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia
    Ismail, Zahinoor
    Black, Sandra E.
    Camicioli, Richard
    Chertkow, Howard
    Herrmann, Nathan
    Laforce, Robert, Jr.
    Montero-Odasso, Manuel
    Rockwood, Kenneth
    Rosa-Neto, Pedro
    Seitz, Dallas
    Sivananthan, Saskia
    Smith, Eric E.
    Soucy, Jean-Paul
    Vedel, Isabelle
    Gauthier, Serge
    [J]. ALZHEIMERS & DEMENTIA, 2020, 16 (08) : 1182 - 1195
  • [19] Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease
    Jack, Clifford R., Jr.
    Wiste, Heather J.
    Vemuri, Prashanthi
    Weigand, Stephen D.
    Senjem, Matthew L.
    Zeng, Guang
    Bernstein, Matt A.
    Gunter, Jeffrey L.
    Pankratz, Vernon S.
    Aisen, Paul S.
    Weiner, Michael W.
    Petersen, Ronald C.
    Shaw, Leslie M.
    Trojanowski, John Q.
    Knopman, David S.
    [J]. BRAIN, 2010, 133 : 3336 - 3348
  • [20] Jia J., 2018, NATL MED J CHINA, V17, P1294, DOI [10.3760/cma.j.issn.0376-2491.2018.17.003, DOI 10.3760/CMA.J.ISSN.0376-2491.2018.17.003]